Drug shortages homepage

Welcome to Drug Shortages Canada, the website for reporting drug shortages and discontinuations in Canada. The Food and Drug Regulations require drug sellers to report when they are not able to meet demand for a product or when they stop selling a product. Information about the website and the regulations can be found on the About & Resources Page.

A shortage means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug is unable to meet the demand for the drug.

A discontinuation means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug, permanently ceases the sale of the drug.

Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:

  • a review of the information gathered on the shortage issue, and
  • a thorough discussion on its potential impact and next steps.

Below are the newest and most recently updated Shortage and Discontinuation reports. Alternatively, please visit the Tier 3 page to see current Tier 3 Drug Shortages and associated shortage or discontinuation reports.

Drug pills

LEGEND

!!T3 denotes an actual Tier 3 shortage/discontinuation

!T3 denotes an anticipated Tier 3 shortage/discontinuation

Shortage Reports

Brand name Company Name Status Strength Update Date Updated View Report
CYMBALTA ELI LILLY CANADA INC Actual shortage 60MG Updated Report 2022-12-07 177305
OXYTOCIN INJECTION, USP FRESENIUS KABI CANADA LTD Actual shortage 10UNIT Updated Report 2022-12-07 160656
SILKIS GALDERMA CANADA INC Actual shortage 3MCG Updated Report 2022-12-07 172363
VENTOLIN HFA GLAXOSMITHKLINE INC Actual shortage 100MCG Updated Report 2022-12-07 177294
MS CONTIN PURDUE PHARMA Actual shortage 30MG Updated Report 2022-12-07 174235
MS CONTIN PURDUE PHARMA Actual shortage 60MG Updated Report 2022-12-07 174238
NUCYNTA EXTENDED-RELEASE ENDO VENTURES LTD. Actual shortage 50MG Updated Report 2022-12-07 169637
NUCYNTA EXTENDED-RELEASE ENDO VENTURES LTD. Actual shortage 150MG Updated Report 2022-12-07 169640
FLOVENT HFA GLAXOSMITHKLINE INC Actual shortage 125MCG New Report 2022-12-07 177285
COLY-MYCIN M SEARCHLIGHT PHARMA INC Actual shortage 150MG Updated Report 2022-12-07 176363

Discontinuation Reports

Brand name Company Name Status Strength Update Date Updated View Report
CLINIMIX BAXTER CORPORATION To be discontinued 200MG 300MG 290MG 240MG 210MG 90MG 1.04G 575MG 340MG 250MG 515MG 20MG 16.6G 365MG 280MG 290MG Updated Report 2022-12-06 118612
AMERGE GLAXOSMITHKLINE INC Discontinued 2.5MG Updated Report 2022-12-02 148430
XELODA CHEPLAPHARM ARZNEIMITTEL GMBH Discontinued 150MG Updated Report 2022-12-01 176355
XELODA CHEPLAPHARM ARZNEIMITTEL GMBH Discontinued 500MG Updated Report 2022-12-01 176359
PMS-FENTANYL MTX PHARMASCIENCE INC Discontinued 12MCG Updated Report 2022-11-25 165397